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Abstract-Non-nucleoside analogs of the pyrrolopyrimidine nucleosides toyocamycin, sangivamycin 
and thiosangivamycin have been synthesized and their cytotoxicity in mammalian cells determined. 
While studying the effects of Rhioamide-substituted analogs on cell growth, we observed an interesting 
phenomenon in which cells recovered spontaneously from growth inhibition during extended incubations. 
HPLC studies demonstrated that the 5-thioamide moiety of several structurally dissimilar 7-substituted 
4-aminopyrrolo[2,3-djpyrimidines, including thiosangivamycin, is unstable in cell culture medium and 
is converted to the corresponding 5-nitrile with a half-life of approximately 48 hr. In contrast, different 
substituents at the 4-position of the heterocycle significantly affected the stability of the 5-thioamide 
moiety. Conversion of the thioamide to the nitrile was caused by components in the cell culture medium, 
not components of serum. The above observations demonstrate that caution should be exercised in 
interpreting biological data obtained in vitro for 5-thioamide pyrrolo[2,3-dlpyrimidines. 
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The pyrrolo[2,3-dlpyrimidine nucleoside antibiotics 
toyocamycin (la, Table 1) and sangivamycin (lb) 
originally were isolated from different strains of 
streptomyces in 1956 and 1963, respectively [l, 21. 
The total synthesis of these compounds was reported 
in 1969 by Townsend and coworkers [3]. A synthetic 
analog, thiosangivamycin (lc), was described in 1970 
by this same research group [4]. All three compounds 
(la-c) are highly toxic to mammalian cells and have 
been evaluated as potential anti-cancer agents [.5,6]. 
Sangivamycin was advanced to phase I clinical trials, 
and a report on its toxicity has been published [7]. 
As part of our ongoing research involving 
pyrrolo[2,3-d]pyrimidines as potential antiviral 
agents [8-141, we recently described the synthesis 
and activity against HCMVt of a number of non- 
nucleoside derivatives related to toyocamycin, 
sangivamycin and thiosangivamycin (la-c) [15]. We 
have expanded our studies in this area and now have 
synthesized a number of closely related compounds 
(Z-6). While studying the cytotoxicity profile of these 
new analogs, we observed an unusual phenomenon 
in which cells spontaneously recovered from growth 
inhibition during extended incubation times. An 
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investigation and an explanation of this phenomenon 
follows. 
MATERIALS AND METHODS 
Materials. Toyocamycin, sangivamycin and thios- 
angivamycin were obtained from the library of 
compounds in the laboratory of one of us (L.B.T.). 
Compounds 2 and 3 were synthesized in four or 
five steps ,from the known 2-amino-5-bromo-3,4- 
dicyanopyrrole [16] by a modification of the 
procedure described in Ref. 15. Compounds 4-6 
were synthesized from the kev intermediate 4-chloro- 
7 - [(i - methoxyethoxy)m&hyl]pyrrolo[2,3 - d] - 
ovrimidine-5-carbonitrile eenerated bv a modifi- 
&ion of the procedure discribed pre;iously [17]. 
No impurities were detected in the ‘H NMR of all 
compounds examined and C-H-N analysis of these 
compounds was within the acceptable +0.4% 
of theoretical values. Details of the synthetic 
procedures, physical characteristics, and antiviral 
activity of compounds 2-6 are being published 
elsewhere. 
Cell cultures. KB cells, an established human cell 
line derived from an epidermal oral carcinoma, were 
grown in MEM supplemented with 10% calf serum 
and were subcultured by conventional methods by 
using 0.05% trypsin plus 0.02% EDTA [8]. The 
average PDT for KB cells in the absence of drugs 
was 21 hr. L1210 murine leukemic cells were grown 
in Fischer’s medium supplemented with 10% heat- 
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Table 1. Structure and cytotoxicity of 4-aminopyrrolo[2,3-dlpyrimidine analogs 
Compound 
RI 
Cytotoxicity, ICKY (FM) 












































Cytotoxicity was determined by measuring the effects of compounds on the growth of 
KB and L1210 cells. Data are the averages of two or more experiments. The greater than 
symbol indicates that the ICY was not reached at the highest concentration tested. 
Compounds la-c are toyocamycin, sangivamycin and thiosangivamycin, respectively. 
inactivated (56”, 30 min) horse serum and were 
subcultured by serial dilution. All cell lines were 
screened periodically for Mycoplasma contamination 
and were negative. 
Cytotoxicity studies. The cytotoxicity of compounds 
la-c to 3a-c was determined initially in KB cells by 
a staining method previously described [18] and in 
an L1210 cell growth assay [19]. In more detailed 
studies, the inhibitory effect of compound 2c was 
evaluated and PDTs were determined in a KB cell 
growth assay [20]. PDTs are significantly longer in 
cells whose growth is inhibited, or whose absolute 
numbers decrease as a result of toxicity affecting 
their growth. PDTs were calculated by means of a 
least squares program fitting the exponential portion 
of a growth curve. For growth studies with KB and 
L1210 cells, growth rates were calculated from 
determinations of the number of cells at 0, 24, 48, 
72 and 96 hr in the presence of selected concentrations 
of the test compound. Cells were enumerated using 
a Coulter Counter (Coulter Electronics, Hialeah, 
FL). Growth inhibition was calculated as the slope 
of a semi-logarithmic plot of cell number against 
time for the treated culture as a percent of the 
control. In both the staining and cell growth studies, 
the ICKY was defined as the concentration required 
to decrease the growth rate to 50% of the control 
rate. 
Compound stability assays. The stability of 
compounds in cell culture medium was investigated 
by incubating 100 @I concentrations of compounds 
l-6 at 37” in tightly capped tubes. The compounds 
were incubated in either Fischer’s medium, MEM, 
or HBS [21] (10 mM HEPES, 137 mM NaCl, 5.4 mM 
KCl, 0.7 mM Na2HP04, 5.6 mM dextrose, pH 6.5). 
In all cases, the incubation media contained neither 
Table 2. Retention times and UV absorbance data of 
pyrrolo[2,3-dlpyrimidine analogs 












































Retention times (RT) were determined by reverse-phase 
HPLC as described in the text. The A,,,,, (nm) of each 
compound was determined by UV spectroscopy. 
cells nor serum. The pH of the medium was 
monitored and was found to be consistently between 
7.5 and 7.8. At selected times during periods 
extending up to approximately 3 weeks, lOO+L 
aliquots of medium or buffer were removed and 
immediately analyzed by reverse-phase HPLC. 
Analytical procedures. HPLC of compounds l-6 
was performed with a Beckman Ultrasphere ODS 
reverse-phase column (5 pm, 4.6 mm X 15 cm). 
HPLC analysis of la-c was adapted from a literature 
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procedure 1221. Compounds la-c were eluted in 
30 min using a linear gradient starting with 0.02 M 
KH2P04 ( H5.6): 60% MeOH/40% Hz0 solution 
(87: 13, v v) and ending with 100% of the 60% P 
MeOH/40% HZ0 solution. Elution of compounds 
2-6 was accomplished in 70 min using a linear 
gradient starting with 0.1% trifluoroacetic acid in 
HZ0 and ending with 50% MeOH. UV absorbance 
of the compounds was monitored simultaneously at 
the A,,,,, for the thioamide and nitrile substituted 
derivatives (Table 2). Retention times (RT) for 
compounds l-4 are shown in Table 2. Peak areas 
were determined using System Gold Software 
(Beckman Instruments, Fullerton, CA). The purity 
of each compound was determined by HPLC before 
the start of each experiment. 
RESULTS 
7-Benzyl-substituted 4-aminopyrrolo[2,3-dlpyrim- 
idine derivatives (Za-t, Table l), related to 
toyocamycin (la), sangivamycin (lb) and thio- 
sangivamycin (lc), were synthesized and examined 
for activity against HCMV as potential antiviral 
agents. Results, described elsewhere [23], showed 
that similar to our previous report on 7-alkyl 
4-aminopyrrolo[2,3-dlpyrimidines [15], only the 
thioamide-substituted derivative (2c) exhibited 
activity against HCMV [23]. We have expanded the 
cytotoxicity portion of those studies and now report 
that the thioamide (2~) was more toxic than the 
carboxamide (2b) in KB cells, but in L121O cells 2b 
was more toxic than 2c (Table 1). In both cell lines, 
the nitrile derivative (2a) was the least toxic. 
Nonetheless, compounds 2a-c were substantially less 
toxic in both KB and L1210 cells when compared 
with the parent nucleoside analogs la-c. Compounds 
3a-c containing a 2-methoxyethoxy methyl side chain 
at N-7, were the least toxic compounds of those 
studied. 
More detailed studies on the effect of compound 
2c on the growth of uninfected KB cells demonstrated 
that it suppressed growth at 10 and 32 PM (Fig. 1). 
Inhibition observed at 32pM was reversible upon 
removal of the drug following a 24-hr incubation 
period (Fig. I), suggesting that it acts as a cytostatic 
rather than a cytotoxic agent. Surprisingly, growth 
resumed even in cultures from which drug was not 
removed (Fig. 1). This observation was supported 
by data from a separate experiment in KB cells 
where PDTs were calculated at 24-hr intervals up to 
72 hr after incubation of 32pM 2c. Over this 72-hr 
period, the PDT increased from 21 hr in the control 
to 56 hr in drug-treated cultures during the first 24- 
hr incubation with 2c. In contrast, the PDT of the 
drug-treated cultures returned to control values 
(20 hr compared with 21 hr in the control) during 
the last 24-hr interval. Similar results were obtained 
in L1210 cells. Together these results suggested that 
2c was being converted to a less toxic compound in 
vitro. Various possibilities were considered for the 
basis for this recovery: (i) inactivation of the 
compound by cellular enzymes, (ii) inactivation by 
enzymes in the serum, or (iii) degradation in cell 
culture medium. Cell growth recovery could not be 
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Fig. 1. Effect of compound 2c on the growth of KB cells. 
Cells were seeded at 40,000 cells/well and incubated for 
24 hr at which time 10 or 32 PM 2c was added to three sets 
of cultures (0, Cl, II) and incubated for an additional 
24 hr. At that time, the medium was removed from one 
set of cultures containing 32yM drug (D), rinsed with 
HBS, and the incubation continued with drug-free medium. 
Cells were harvested at the time periods indicated and 
enumerated with a Coulter Counter. 
inactivating the compound since preincubation of 
100 yM compound 2c in medium without serum for 
2 days before the addition of cells eliminated 
inhibition of L1210 cell growth. In this experiment, 
L1210 cell growth in drug-treated cultures was 
comparable to the control values even though the 
concentration of 2c used was approximately 1.5 
times the IQ~. Therefore, we concluded that 
compound 2c was unstable in cell culture medium 
alone (without serum) and was spontaneously 
converting to a relatively non-toxic compound. 
To investigate this phenomenon, 100pM com- 
pound 2c was incubated in serum-free Fischer’s cell 
culture medium. HPLC analysis was performed on 
samples of cell culture medium removed at 24-hr 
intervals. Within the first 48 hr of incubation, more 
than half of 2c was converted to a new product (Fig. 
2). By 144 hr, nearly all of 2c was converted to this 
new product. HPLC analysis using both 2a and 2b 
as markers showed that this new peak co-eluted with 
the co~esponding nitrile (2a). From this it was 
calculated that the thioamide (2~) was converted to 
2a with a T112 of 41 hr. Upon close examination of 
the HPLC chromatograms, a small amount of the 
nitrile, 2a, and a peak which co-eluted with the 
carboxamide (2b) were observed at t = 0. These 
trace amounts most likely were impurities in 2c that 
were not detected by either ‘H NMR or C-H-N 
analysis used to characterize 2~. It should be noted 
that the peak 2b did not change over the 144-hr 
incubation period (Fig. 2), indicating that the 
carboxamide was not an intermediate in the 
conversion of 2c to 2a. Further HPLC analysis 
demonstrated that incubation of the nitrile (2a) and 
the carboxamide (2b) for 4 days under the same 
conditions as those used for 2c resulted in no change 
from the t = 0 elution pattern. This indicated that 
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Fig. 2. Chromatograms of Fischer’s medium without serum 
incubated for 0, 48 and 144 hr at 37” with 100 ,uM 2c. 
Absorbance of the effluent was monitored simultaneously 
at 280 and 294 nm; absorbance at 280 nm is presented. 
Peaks other than those labeled 2a, 2b or 2c are from 
components of Fischer’s medium. These peaks were 
unchanged during the experiment and were observed in a 
sample not incubated with 2c. Key: (2a) 4-amino-7- 
(benzyl)pyrrolo[2,3-dlpyrimidine-5-carbonitrile; and (2b 
and 2c) the corresponding S-carboxamide and S-thio- 
carboxamide, respectively. 
these two compounds were stable under the culture 
conditions. These results further demonstrate that 
the carboxamide cannot be an intermediate in the 
conversion of the thioamide to the nitrile. Additional 
studies in which 2c was incubated in medium 
containing serum and with cultured KB cells gave 
results similar to those obtained for 2c in cell and 
serum-free medium. 
These results prompted us to examine whether 
the conversion in cell culture medium of a thioamide 
moiety to a nitrile was a general phenomenon with 
7-substituted 4-aminopyrrolo[2,3-d]pyrimidine-5- 
thioamides. To test this question, we investigated 
the stability of a related series of compounds, 3a-c 
(Table l), We chose this series for two reasons: (i) 
the ether substituent at N-7 of 3a-c was structurally 
different than the benzyl group of 2a-c and (ii) in 
contrast to 2a-q 3a-c were non-toxic at 100pM in 
both KB and L1210 cells (Table 1). Compound 3c 
was incubated for 5 days under the conditions 
described previously. HPLC analysis demonstrated 
that 3c was converted to a single product that co- 
eluted with the nitrile, 3a, with a T1jZ of 50 hr. In 
contrast to the studies with 2c, a peak that co-eluted 
with the carboxamide, 3b, was not detected from 
t = 0 through the S-day incubation period. As with 
compound 2a, compound 3a was stable under the 
incubation conditions as monitored by HPLC. 
Based upon these findings, the stability of the 
parent nucleosides toyocamycin (la), sangivamycin 
24 
Toyocamycin 
0 50 loo 150 200 250 300 
Time (hours) 
Fig. 3. Stability of the pyrrolopyrimidine nucleoside 
thiosangivamycin in cell culture medium. Thiosangivamycin 
was incubated in Fischer’s medium without serum for 11 
days. Aliquots were removed at the times indicated and 
analyzed by HPLC. The peak areas presented in the figure 
are those determined at the &, for each nucleoside 
(274 nm for toyocamycin and 292 nm for thiosangivamycin) 
The peak area at later time points for toyocamycin is 
greater than the peak area for thiosangivamycin at t = 0 
because the molar absorptivity (E) for toyocamycin at 
274 nm is greater than the &for thiosangivamycin at 292 nm 
L3.41. 
(lb) and thiosangivamycin (lc) was also studied. 
Like studies with 2c and 3c, the stability of 
thiosangivamycin was examined by incubating it in 
Fischer’s medium without serum for 11 days and 
analyzing samples by HPLC at selected times during 
this period. The results showed (Fig. 3) that like 2c 
and 3c, thiosangivamycin was converted to a product 
that co-eluted with toyocamycin (la) with a TQ = 
55 hr. Similar results were obtained by incubating 
the compound in MEM without serum (T,,, = 41 hr). 
Like the studies with 3c, a peak that co-eluted with 
sangivamycin (lb) was not detected from t = 0 
through the 11-day incubation period. As with 2a- 
b and 3a, toyocamycin and sangivamycin were stable 
under the incubation conditions. 
To examine the possible role that components of 
cell culture medium had on the conversion of the 
thioamide to the nitrile, a number of studies using 
buffered solutions or modified cell culture medium 
were undertaken. The results showed that contrary 
to those obtained in Fischer’s medium and MEM, 
incubation of lc in HBS resulted in only a very slow 
conversion to the nitrile (TI,? > 504 hr). This 
conversion of thiosangivamycin (lc) to the cor- 
responding nitrile in HBS was > 10 times slower than 
in cell culture medium, strongly suggesting that 
components contained in culture medium but not in 
HBS catalyzed the conversion. To investigate the 
role in the conversion of certain components in the 
medium, the pH of the HBS solution containing lc 
was increased from 6.5 to 7.6, but this did not affect 
the stability of the compound. Additionally, the 
benzyl derivative 2c was incubated with MEM, which 
did not contain phenol red and glutamine. In this 
Cytotoxicity and conversion of thiosangivamycin analogs 
Table 3. Structure, cytotoxicity and stability of several 4-substituted pyrrolo[2,3-dlpyrimidine 




Cytotoxicity, lcso (PM) 
KB L1210 Half-life (hr) 
4a HNMe CN >loo >I00 NA* 
b HNMe CSNHz >lOO >lOO 20 
5a N(Meh CN >loo >lOO NA 
b N(Me), CSNHl >lOO >lOO 150 
6a H CN >I00 >lOO NA 
b H CSNHP >lOO >lOO 175 
Cytotoxicity was determined by measuring the effects of compounds on the growth of KB 
and L1210 cells. Data are the averages of two or more experiments. The greater than symbol 
indicates that the ICKY was not reached at the highest concentration tested. 
* Not applicable. 
medium, the T1/Z was extended from 41 hr to 
approximately 65 hr demonstrating that although 
these two components affected the stability of the 
thioamide moiety, they could not completely account 
for the conversion. 
To investigate whether changes on the heterocycle 
at sites other than N-7 could affect the stability of 
the thioamide group, we examined the effect of 
modifications at the 4-position of 3c on the half-life. 
In this study, the 4-amino group of compound 3 was 
replaced with a proton (H), a methylamino group 
(NHCHs) or a dimethylamino group (N(CHs)z)- 
compounds 4-6 (Table 3). Like compounds 3a-c, 
compounds 4-6 were essentially non-toxic in both 
KB and L1210 cells with ICKY values >lOO ,uM (Table 
3). Like compounds 1-3, compounds 4-6 were 
incubated in Fischer’s medium, and their stability 
was monitored by HPLC. The results demonstrated 
that modifications at the 4-position have a definite 
effect on the stability of the 5thioamide moiety, 
whereas changes at N-7 tend not to affect the stability 
of the .5-thioamide moiety (Table 3). For example, 
replacement of the 4-amino group of 3c with a 
methylamino group (4b) decreased the stability of 
the thioamide (T,,z = 20 hr). In contrast, replace- 
ment with a dimethylamino group (Sb) or a hydrogen 
(6b) extended the Ti/* from 50 hr for 3c to 150 hr 
for 5b and 175 hr for 6b. In the case of 5b, we also 
observed an unidentified peak by HPLC in addition 
to 5a and Sb. This possible intermediate appeared 
24 hr into the incubation and rapidly decreased 
thereafter. This was the only compound during this 
entire study where we observed an HPLC peak other 
than the thioamide or nitrile analogs. 
pyrrolopyrimidine nucleoside thiosangivamycin and 
several related analogs are converted to the 
corresponding nitrile analogs in cell culture medium. 
The conversion of thiosangivamycin to toyocamycin 
in cell culture medium has not, to the best of our 
knowledge, been observed previously. Even if the 
conversion had occurred in previous studies, there 
would have been no obvious reason to suspect this 
since thiosangivamycin and toyocamycin are equally 
toxic to mammalian cells. The toxicity of thiosan- 
givamycin and toyocamycin arises because both 
compounds are phosphorylated by adenosine kinase 
[24] to afford the 5’-monophosphate derivatives that 
ultimately are incorporated into DNA or RNA 
[5,6]. Whether the 5’-monophosphate of thiosan- 
givamycin is converted to phosphorylated toyo- 
camycin is unknown and was not included in the 
present study. However, our results, uide supru, 
suggest that this would occur since a variation of the 
substituent at N-7 does not seem to have a major 
effect on the conversion. 
DISCUSSION 
It is interesting that changes at the 4-position can 
have a major effect on the stability of the 5- 
thiocarboxamide moiety. This would suggest that 
the 4-position may play a key role in stabilizing or 
destabilizing the 5-thioamide group. Results obtained 
for the 4-substituted amino derivatives (4b and 5b) 
revealed that increasing the basicity of the amino 
group at C-4 does not necessarily correlate with an 
increase or decrease in the stability of the thioamide. 
Instead, the stability of a substituted thioamide 
compound seems directly related to the presence or 
absence of an amino group with a free proton at 
C-4. Whether modifications at other sites on the 
heterocycle could affect the stability of the thioamide 
group is unknown. 
The present study has established that the The rapid conversion of 2c to its corresponding 
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nitrile (2a) in cell culture medium raises an interesting 
issue regarding the antiviral activity. We have 
demonstrated [23] that 2a is inactive against HCMV 
at concentrations up to lOO,uM, whereas 2c has 
potent activity against HCMV with an IC~,~ = 0.4 ,uM. 
Our present results suggest that the action of 2c 
against HCMV must occur rather rapidly since by 
48 hr essentially 50% of the active compound is 
converted to an inactive one. We provided evidence 
for this hypothesis while studying the temporal effect 
of 2c on DNA and RNA synthesis [23]. We showed 
that in uninfected cells, various concentrations of 2c 
dramatically affect both DNA and RNA syntheses 
approximately 1-2 hr following its addition to 
cultured CEM-SS cells. These results, however, were 
obtained in uninfected cells and whether the potent 
early inhibition of RNA and DNA syntheses by 2c 
in uninfected cells correlates with the potent activity 
against HCMV has yet to be established and is 
currently under investigation. 
Beside the nitrile derivatives, the identity of any 
other product involved in the conversion is unknown. 
Since lc, 2c, 3c and 4b exhibit similar stability patterns 
but completely different cytotoxicity profiles, it 
is highly unlikely that the release of H?S as a by- 
product of the conversion caused cell toxicity. 
Regarding the causes of this phenomenon, the 
identification of a single component has proved to 
be difficult. Our results suggest that there may be a 
combination of components, such as phenol red and 
glutamine, that are involved in catalyzing the 
observed conversion. Chemically, thioamides can be 
converted to nitriles by treatment with mercuric 
chloride and methylamine [25,26]. In the current 
study, these reagents were not present during the 
incubation of any of the thioamide-substituted 
derivatives. There have been reports, however, of 
more mild reaction conditions furnishing a nitrile 
from a thioamide [4, 271. Specifically, alkylation of 
thiosangivamycin (lc) with methyl iodide afforded 
a 5methylthioformimidate intermediate that rapidly 
eliminated methanethiol to give toyocamycin (la). 
Similar results were obtained upon treatment of 5- 
amino - 4 - thiocarboxamide - 1 - B - D - ribofurano- 
sylimidazole (thio-AICA-riboside) with methyl 
iodide. From this information it may not be entirely 
unreasonable to propose the formation of an 
alkylated thio-intermediate that can rapidly eliminate 
to give the nitrile. The possible appearance of an 
intermediate in the conversion of 4-dimethylamino- 
7-[(2-methoxyethoxy)methyl]pyrrolo[2,3-d]pyrim- 
idine-5thiocarboxamide (5b) to the corresponding 
nitrile (5a) may support this argument; however, the 
exact mechanism of how the thioamide is converted 
to the nitrile in cell culture medium is unknown. 
In summary, our results have demonstrated that 
the 5-thioamide moiety of many 7-substituted 4- 
aminopyrrolo[2,3-dlpyrimidines is unstable in cell 
culture medium, and is converted to the cor- 
responding 5-nitrile regardless of the substituent at 
N-7. In contrast, substituents at the 4-position of the 
heterocycle significantly affect the stability of the 5- 
thioamide moiety. Investigators using these or 
structurally similar compounds should be aware of 
these results and appreciate that biological data 
generated in cell culture may be due to a mixture of 
the thioamide and by-product(s) of the conversion. 
Acknowledgements-We thank Julie Breitenbach and 
Patricia Whittler for their expert technical assistance. This 
research was supported by Department of Health and 




Nishimura H, Katagiri K, Sato K, Mayama M and 
Shimaoka N, Toyocamycin, a new anti-candidia 
antibiotic. J Antibiot (Tokyo) 9A: 60-62, 1956. 
Rao KV and Renn DW, BA-90912: An antitumor 
substance. Antimicrob Agents Chemother 77-79. 1963. 
Tolman RL, Robins RK and Townsend LB. Pyr- 
rolopyrimidine nucleosides. III. The total synthesis of 
toyocamycin, sangivamycin, tubercidin and related 
derivatives. I Am Chem Sot 91: 2102-2108, 1969. 
Hinshaw BC, Gerster JF, Robins RK and Townsend 
LB, Pyrrolopyrimidine nucleosides. V. A study on the 
relative chemical reactivity of the 5-cyano group of the 
nucleoside antibiotic toyocamycin and 
desaminotoyocamycin. The synthesis of analogs of 
sangivamycin. .I Org Chem 35: 236-241, 1970. 
“. Glazer RI and Peale AL. Comparison between the 
inhibitory activities of sangiiamycin and thio- 
sangivamycin on nuclear ribonucleic acid synthesis in 
L1210 cells in uirro. Biochem Pharmacol29: 305-310. 
1980. 
6. Ritch PS and Helmsworth M. Pyrrolopyrimidine 
lethality in relation to ribonucleic acid synthesis in 
Sarcoma 180 cells in oitro. Riochem Pharmacol 31: 
26862688. 1982. 
7. Cavins JA, Hall TC, Olson KB, Khung CL, Horton J, 
Colsky J and Shadduck RK, Initial toxicity study of 
saneivamvcin fNSC-65346). Cancer Chemother Ren 51: 
1971200, i967: 






Krawczyk SH, Townsend LB and Drach JC, 
Pyrrolo[2,3-dlpyrimidine nucleosides as inhibitors of 
human cytomegalovirus. Antimicrob Agents Chemother 
31: 544-550, 1987. 
Gupta PK. Daunert S, Nassiri MR, Wotring LL, Drach 
JC and Townsend LB, Synthesis, cytotoxicity and 
antiviral activity of some acyclic analogues of 
the pyrrolol2,3-dlpyrimidine nucleoside antibiotics 
tubercidin. toyocamycin and sangivamycin. J Med 
Chem 32: 402-408, 1989. 
Gupta PK, Nassiri MR, Coleman LA, Wotring LL, 
Drach JC and Townsend LB, Synthesis, cytotoxicity. 
and antiviral activity of certain 7- [(2 hydroxy- 
ethoxy)methyl]pyrrolo[2,3 - dlpyrimidine nucleosides 
related to toyocamycin and sangivamycin. J Med Chem 
32: 1420-1425, 1989. 
Birch GM, Krawczyk SH, Townsend LB and Drach 
JC. Antagonism of the cytotoxic but not antiviral 
effects of ara-sangivamycin by adenosine. Anfimicrob 
Agents Chemother 33: 16061608, 1989. 
Saxena NK, Coleman LA, Drach JC and Townsend 
LB, Synthesis and antiviral activity of some 7- 
(2 - hydroxyethoxymethyl)pyrazolo[3,4 - dlpyrimidine 
analogs of sangivamycin and toyocamycin. J Med Chem 
33: 1980-1983, 1990. 
Townsend LB, Drach JC. Wotring LL, Vittori S, Pudlo 
JS, Swayze EE, Gupta P, Maruyama T, Saxena N, 
Coleman L, Westerman AC, Spurr J, Nassiri MR, 
Turk SR and Krawczyk SH, Design, synthesis. and 
studies on the structure activity relationships of certain 






Cytotoxicity and conversion of thiosangivamycin analogs 807 
related analogs as potential antineoplastic and antiviral Townsend LB and Drach JC, Flow cytometric 
agents. Farmaco 46: 113-139, 1991. evaluation of the cytotoxicity of novel antiviral 
Renau TE, Nassiri MR, Swayze EE, Townsend LB compounds. Cytometry 11: 411-417, 1990. 
and Drach JC, Improved synthesis and biological 21. Shipman C Jr, Control of culture pH with synthetic 
evaluation of an acyclic thiosangivamycin active against buffers. In: Tissue Culture. Methods and Applications 
human cytomegalovirus. Antiuiral Res 19: E--28,1992. (Eds. Kruse PF Jr and Patterson MK Jr), pp. 709-712. 
Renau TE, Ludwig MS, Drach JC and Townsend Academic Press, New York, 1973. 
LB, Design, synthesis and activity against human 22. Krstulovic AM and Brown PR, Reversed-Phase High 
cytomegalovirus of non-phosphorylatable analogs of Performance Liquid Chromatography, pp. 236241. 
toyocamycin, sangivamycin and thiosangivamycin. Wiley-Interscience, New York, 1982. 
Biorg Med Chem Lett 2: 1755-1760, 1992. 23. Renau TE, Young CG, Nassiri MR. Lee JS, Wotring 
Swayze EE, Hinkley JM and Townsend LB, 2- LL, Townsend LB and Drach JC, Antiherpetic activity, 
Amino-5-bromo-3,4-dicyanopyrrole. In: Nucleic Acid cytotoxicity and metabolism of non-nucleoside analogs 
Chemistry; Improved and New Synthetic Procedures, related to toyocamycin, sangivamycin and thio- 
Methods and Techniques, Part IV (Eds. Townsend LB sangivamycin. Antiuiral Res [Suppl] 1: 118, 1993. 
and Tipson RS), pp. 16-18. Wiley-Interscience, New 24. Miller RL, Adamczyk DL, Miller WH, Koszalka GW, 
York, 1991. Rideout JL, Beacham LM, Chao EY, Haggerty JJ, 
Hinshaw BC, Leonoudakis 0, Schram KH and 
Townsend LB, Pyrrolopyrimidine nucleosides. Part X. 
Synthesis of certain 4,5_disubstituted 7 - (B-D - 
ribofuranosyl)-pyrrolo[2,3-dlpyrimidines related to 
toyocamycin and sangivamycin. J Chem Sot Perkin 
Trans I12481253, 1975. 
Prichard MN, Prichard LE, Baguley WA, Nassiri MR 
and Shipman C Jr, Three-dimensional analysis of the 
synergistic cytotoxicity of ganciclovir and zidovudine. 
Antimicrob Agents Chemother 35: 1060-1065, 1991. 
19. Wotring LL and Townsend LB, Study of the cytotoxicity 
and metabolism of 4-amino-3-carboxamido-l-(/3- 
D - ribofuranosyl)pyrazolo[3,4 - d]pyrimidine using 
inhibitors of adenosine kinase and adenosine deami- 
nase. Cancer Res 39: 3018-3023, 1979. 
20. Nassiri MR, Hudson JL, Pudlo JS, Birch GM, 
Krenitsky TA and Elion GB, Adenosine kinase from 
rabbit liver. II. Substrate and inhibitor specificity. J 
Biol Chem 254: 2346-2352, 1979. 
25. Shaw G and Butler DN, Purines, pyrimidines and 
glyoxalines. .Part XIV. The preparation and some 
reactions of cY-amino-a-cyanothioacetamide, leading to 
6-mercaptopurines and adenines. J Chem Sot 4040- 
4045, 1959. 
26. Earl RA and Townsend LB, Pyrazolopyrimidine 
nucleosides. Part VII (1). The synthesis of certain 
pyrazolol3,4-dlpyrimidine nucleosides related to the 
nucleoside antibiotics toyocamycin and sangivamycin. 
J Heterocycl Chem 11: 1033-1039, 1974. 
27. Yamazaki A, Kumashiro I, Takenishi T and Ikehara 
M, Synthesis of thio-aica, 6-thioxanthine, isoguanine 
analogs and their ribosides. Chem Pharm Bull (Tokyo) 
16: 2172-2181, 1968. 
